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ABSTRACT 
In an effort to clarify the role of mast cell derived mediators 
(particularly histamine) in the pathogenesis of exercise induced 
asthma (EIA), twelve mild asthmatic subjects underwent exertional 
challenges following pretreatment with either aerosolized saline 
placebo, or the H-j antagonist, chlorpheniramine maleate. Equivalent 
intrapulmonary thermal burdens were ensured by having each subject 
perform identical exercise tasks on a cyclergometer, while maintaining 
inspired air conditions at a constant temperature and low humidity 
with resulting equivalence of baseline, final minute and total minute 
ventilation throughout the study. All subjects exercised a total 5 to 
7 minutes on each of the following three study days; a screeening day, 
during which no pretreatment was administered and each subject was 
determined to have EIA by demonstrating at least a 15% postexercise 
decline in the MEF40%(P), and the two randomly assigned protocol days, 
wherein each subject was administered in double blind fashion, the 
placebo or antihistamine. 
Pulmonary function tests revealed parallel, signficant immediate 
post inhalation declines in FEV-j (0.23 and 0.11 liter) and the MEF40%(P) 
(0.39 and 0.36 1/s) on both the antihistamine and placebo days respectively. 
By thirty minutes post inhalation, however, both the FEV-j (2.94 ± 0.69 vs 
2.65 ± 0.74 liter: mean ± S.D.) and the MEF40%(P) (2.32 ± 1.19 vs 1.80 
± 0.94 1/s, mean ± S.D.) had risen exclusively and significantly (p<0.05) 
on the antihistamine day. Although both the FEV-j and the MEF40%(P) remained 
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significantly (p< 0.01) higher five minutes after exercise on the antihistamine 
day (i.e. 2.82 ± 0.70 vs 2.48 ± 0.83 liters, and 1.67 ± 0.79 vs 1.34 ± 0.73 1/s 
mean ± S.D., respectively), analysis revealed statistically equivalent 
declines in both parameters, when the change from 30 minutes post 
inhalation to 5 minutes post exercise were compared. Finally, pulmonary 
function as determined by both the FEV-j and the MEF40(P), were found to be 
greatly improved (p< 0.01) following post exercise administration of 
metaproterenol. 
Based upon the observed effects of chlorpheniramine maleate, we 
conclude that a low grade release of mast cell derived histamine does in 
fact contribute to the increase in resting bronchomotor tone found in 
asthmatics. However, the failure of this potent antihistamine to prevent 
EIA, suggests that histamine is not an independent and central mediator 
of post exercise asthma. 
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I. Background and Literature Review 
A. INTRODUCTION 
"Asthma is a disorder characterized by an increased responsiveness 
of the trachea and bronchi to various stimuli in widespread narrowing 
of the airways, the severity of which changes either spontaneously 
or as a result of therapy"."' The pathogenesis of this airway narrowing 
is known to include varying degrees of bronchial smooth muscle contraction, 
mucosal edema and inflammation, as well as an overproduction and inspissation 
4 
of mucus . This disease entity, manifested symptomatically by the triad 
of intermittent wheezing, dyspnea and coughing is estimated to affect 3-4 
2 3 percent of the population of the U.S. ’ . Though much has been learned 
about asthma over the past few decades, it is readily apparent to the 
student of medicine, that such a common, often frightening and debilitating 
disease, necessitates continued research to further elucidate the pathogenetic 
mechanisms in the hope of defining more efficacious prophylactic and 
therapeutic interventions. 
One of the most commonly used classifications divides asthma into 
two clinicopathologic entities: "Extrinsic" or "Allergic Asthma", and 
"Intrinsic" or "Nonallergic Asthma". This nosology has enabled 
researchers and writers to distinguish groups of patients based on 
epidemiologic, etiologic and clinical factors. Thus, patients with 
extrinsic asthma are generally characterized by an atopic history and 
childhood onset, with more intermittent and acute exacerbations of an 
often milder form of airway narrowing, triggered by inhalation of dusts, 
pollens and dander etc..., as well as other antigenic stimuli. It is 
the binding of these allergens to mast cell bound IgE leading to a Type I 
hypersensitivity reaction and the release of mediators (see below) which 
Q 
results in airway narrowing. In intrinsic asthma patients with "hyperactive 
airways"^, respond in a more chronic and often severe nature to many 
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nonantigenic stimuli. These patients without allergic histories, commonly 
recognize the symptoms of wheezing, dyspnea and coughing following upper 
respiratory infections or exposure to various pollutants usually beginning 
after age 30. The pathophysiologic pathway(s) unlike that described for 
extrinsic asthma are less clearly defined. It is currently thought that 
intrinsic asthma involves neurogenic reflexes , certain immunologic 
mechanisms with mediator release^ and adrenergic receptor imbalance'7, 
each acting alone or in combination, as well as other poorly elucidated 
mechanisms. 
This categorization of asthma into subgroups of extrinsic and intrinsic 
forms has often been criticized^, since most patients manifest clinical 
features common to both. One example of a stimulus evoking bronchoconstriction 
8 10 in almost all asthmatics ’ , often attributed to the state of bronchial 
hyperirritabil ity^5'*'^ present in all those with the disease, is exercise 
induced asthma (EIA). Interest surrounding this stimulant of reversible 
airway narrowing concerns not only its implications for the health and 
well being of those afflicted with it, but additionally, exercise has 
become recognized as a diagnostic aid and clinical tool for the evaluation 
23 24 
of various therapeutic modalities used for asthma in general1" ’ 
Moreover, exercise, a physiologic, reproducible and easily controlled 
variable in the research laboratory has enabled investigators utilizing 
it as a provocation of reversible bronchial obstruction to further their 
115 
understanding of the pathogenetic process of asthma itself 
Although recent work on EIA has defined that heat flux and airway 
cooling as the initial link in the pathophysiologic chain of events leading 
11 12 
to bronchoconstriction , controversy continues as to how this thermal 
stimulus (cold) translates into bronchial narrowing. Some authorities believe 
. 
5 
13 
that it is the activation of mast cells (see below) with release of 
chemical mediators such as histamine and SRS-A which then act directly 
on bronchial smooth muscle causing airway narrowing, that is the critical 
event following airway cooling in EIA. 
The present study is intended to test the hypothesis that mast cell 
derived mediators, specifically histamine, is involved in the causation 
of EIA. By administering a potent aerosolized H-j blocker, chlorepheneramine 
maleate, prior to exercise, and evaluating its effect on postexertional 
asthma, it is hoped that further insights will be gained regarding the 
nature of EIA in particular and asthma in general. 
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?n 
B. History of EIA£ 
The earliest historical record of the association of strenuous 
physical exertion and airway obstruction dates back to Aretaeus the 
Cappodocian1^ (roman era), centuries after Hippocrates1^ first described 
the asthmatic condition. Aretaeus succinctly noted: 
"If from running, gymnastic exercises or any other work, the 
breathing becomes difficult, it is called asthma""^,16. 
It was not until the 17th century when Willis1^ (1679) eloquently 
redescribed this phenomenon: 
"Whatsoever therefore makes the blood boyle or raises into 
effervescence as violent motion of the body or mind, excess 
of extern cold or heat ... both doth cause asthmatical assaults 
to such as predisposed". 
18 Twenty years later, Sir John Floyer (1698) not only realized the existence 
of a cause and effect relationship between exercise and airway obstruction 
by writing: 
"All violent exercise makes the asthmatic to breath short", 
he additionally, quite astutely recorded the graded symptomatic obstructive 
effects of differing forms of exercise and levels of ventilation. He noted: 
"The most agreeabel exercise is riding, the greatest are sawing, 
bowling, swinging, dancing. Walking is more vehement than riding..., 
those exercises that move the arms, exercise the lungs most." 
During the 19th century the notion (believed by many researchers 
until recently11”*’^) that exercise only caused obstructive symptoms in 
21 distinct group of asthmatics was promo!gated by Salter (1868), when he 
recorded that: 
"Exertion was an exciting cause of symptoms"... 
in 54 of 223 patients studied. 

7 
The modern era utilizing objective measures in the study of EIA 
was ushered in by-Herxheimer (1946). By recording postexercise changes 
in the vital capacity of asthmatic individuals, he demonstrated a crude 
though noble attempt to quantify the subjective phenomena that had been 
observed previously. Though his hypothesis that airway narrowing was 
caused by the hyperventilation associated with exercise was to be 
22 
corroborated some 30 years later , his reasoning was erroneous, in that 
he attributed hyperventilation induced asthma to the development of 
hypocapnia. Nevertheless, it was Herxheimer's work that lit the fuse 
leading to an explosion of interest and information to follow on EIA. 
C. Mechanism of EIA 
1. Background 
The pathogenetic pathway leading to EIA has been the subject of 
intensive investigation since Herxheimer published his findings in a paper 
19 
entitled, "Hyperventilation asthma" . Over the next 30 years many 
29 30 
researchers followed his lead and focused on hypocapnea ’ as well as 
26 28 hyperventilation ’ as possible triggers of bronchospasm in asthmatic 
individuals. Hafez and Crompton implicated hypocapnia as the cause 
of EIA by demonstrating significant decreases in the FEV-j after hyper¬ 
ventilation not matched when hyperventilation was subsequently induced by 
25 CO^ inhalation. Chan-Yeung et al. however, provided evidence to support 
hyperventilation per se, with or without commensurate hypocapnia as the 
critical determinant of EIA. Specifically, they demonstrated a fall in the 
FEV-j in only 3 of 7 patients following exercise, whereas all seven subjects 
were shown to have significant falls in their FEV-j following voluntary 
hyperventilation inhaling both room air and air with 5.6% CO^ content. In 
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another theory, proposed by Vassallo et al. , the release of lactic 
acid from exercising muscle and the subsequent development of acidemia 
was thought to act either directly or indirectly in the causation of 
bronchospasm. Additional hypotheses concerning reflex bronchoconstriction 
32 
mediated by the vagus nerve were suggested by Schiffman et al. , who 
proposed that exercise induced metabolic alterations stimulated the carotid 
33 body, and Zeballos et al. , who posited stimulation of the pharyngeal 
receptors by cold, dry air as forming the afferent loop in the reflex arc. 
34 While others proposed adrenergic abnormalities , a strong body of literature 
developed in support of mast cell degradulation and mediator release in 
the pathogenesis of EIA (see below)."'0,13 
Though no consensus has yet been reached as to the complete patho¬ 
physiologic series of events resulting in EIA, formulation of the initating 
stimulus, as well as clarification of many seeming inconsistencies in the 
16 22 literature has been accomplished by McFadden and Ingram et al. 9 
2. Heat Flux as the Initiating Stimulus in EIA 
35 At first Strauss et al. determined that production of bronchial 
obstruction necessitated an exercise workload that placed sufficient 
stress on either the arms or legs to cause hyperventilation, hypocapnia 
and lactic acid production. This determination indicated that no specific 
exercising muscle group was more asthmagenic than any others. Further 
OC 
experiments were performed by McFadden et al. to isolate the effects 
of hyperpnea and hypocapnia. Their results demonstrated that neither 
adequately explained the development of EIA. They then eliminated lactate 
as a potential mediator responsible for bronchoconstriction when its 
intravenous injusion in levels equivalent to those generated during 
exercise failed to cause airway obstruction . Furthermore, by exercising 
. 
9 
subjects to exhaustion while concurrently infusing sodium bicarbonate to 
normalize pH, and then demonstrating undiminished attacks of EIA, Strauss 
37 
et al. eliminated the role of acidemia in the production of postexercise 
obstruction. 
Though it was a well known clinical observation that asthmatic 
individuals complained of exacerbations of their disease when exposed to 
113 
certain weather extremes , the importance of these subjective experiences 
were not put into an objective perspective until recently. Specifically, 
since it had always been believed that a dry climate was beneficial to 
asthmatics (consistent with the popularity of Arizona amongst asthmatic 
individuals), it came as quite a surprise when a study in Israel by Bar-Or 
38 
et al , demonstrated that asthmatic children developed greater degrees 
of EIA when challenged in a dry climate as compared to more humid 
39 
environments. Similar observations by Weinstein et al. , who recorded a 
29.5% drop in the FEV-j of children exercising in a dry environment as 
compared with only a 13.5% decline while inhaling nebulized saline supported 
38 the findings of Bar-Or . Additionally, to ascertain the effects of 
40 breathing cold air, Strauss et al. , had subjects perform identical exercise 
tasks on a cyclergometer alternately breathing air at ambient and 
subfreezing temperatures. By simply reducing the air temperature, they 
demonstrated an increase in the postexercise decline in the FEV-j from 21% 
to 40%. 
Thus, it had become reasonably clear that breathing cold, dry air 
acted in a synergistic fashion to potentiate the bronchoconstrictive 
effects of exercise. 
To evaluate the possibility of increased efferent vagal tone 
brought about by the thermal (cold) stimulus. Deal et al.^ exercised 
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9 subjects who again breathed air at ambient and subfreezing temperatures, 
but with the added variable of concurrent atropine inhalation. They 
found that the cholinergic blockade in no way hindered the potentiating 
effect of cold air inhalation and postulated that EIA resulted from the 
local effects of incompletely conditioned air in the intrathoracic airways. 
They supported this theory by recording low intraesophageal temperatures 
40 during the performance of exercise in ambient air , which declined even 
further when the temperature and the water content of the inspirate 
42 43 
were decreased . Further evidence was provided by Strauss et al. , who 
demonstrated the elimination of EIA by having patients exercise while 
inspiring air at body temperature and 100% humidity. 
44 When Deal et al. reviewed the data collected in the preceding 
experiments, they found a striking correlation between respiratory heat 
loss and the magnitude of the postexercise obstruction. In a final 
experiment. Deal et al.^, ironically recapitulating certain aspects of 
19 Herxheimer's theory of hyperventilation asthma , demonstrated that the 
operative mechanism in the production of EIA, was hyperventilation with 
subsequent airway cooling. This was accomplished by having subjects 
voluntarily breath, at minute ventilation equal to those attained while ' 
exercising, air conditioned to various temperatures and humidity. They 
found^ that at equivalent minute ventilations, breathing subfreezing 
air, room air, and saturated room air, resulted in 39, 28, and 11% declines 
in the FEV-j respectively. Significantly, hyperventilation of air heated 
to body temperature at 100% humidity resulted in no airway obstruction 
whatsoever. 
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As a result of these experiments, the heat flux hypothesis was 
formulated as a unifying concept, clarifying many previously confusing 
findings in the literature on EIA ’ . The following is a brief 
summary. 
During physical exertion, ventilation increases to meet the 
metabolic demands imposed by working muscles. This necessitates 
inhalation of large volumes of air at ambient conditions. The body 
provides for initial conditioning of this air by transferring heat and 
humidity from the nasal mucosa. However, at such high minute ventilations, 
much of the inspirate reashes the interthoracic airways unchanged. Before 
gaseous exchange can take place at the alveoli, this air must be warmed 
to 37°C and saturated with water vapor. This is accomplished by heat 
transfer and water evaporation from the bronchial mucosa, which results 
in a mucosal temperature decline. The colder the inspired air the greater 
the heat transfer and consequently the larger temperature decline of the 
airways. Similarly,the drier the inspired air, the greater the evaporation 
of mucosal water, again resulting in larger temperature declines. 
Additionally, for any set of conditions of air temperature and humidity, 
the larger the minute ventilation, the greater the heat transfer. Why or 
how ventilation is increased is inconsequential. As shown^ hyperventilation 
and exercise, produce equivalent degrees of airway obstruction as long as 
the same quantity of air, of equal temperature and humidity is inspired. 
With the formulation and general acceptance of the heat flux hypothesis, 
uncontrolled environmental conditions in various laboratories could now 
be implicated as the heretofore unknown confounding variables that led 
confusion and disagreement concerning the reproducibility as well as the 
prevalence of EIA^’45. 
. 
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Additionally, application of these tenets, reconcile the alleged 
differences in the asthmagenicity of such tasks as: walking, running, 
46 47 35 
cycling and swimming ’ . As demonstrated by Strauss et al. , equivalent 
exercise stress, whether performed by arm or leg work, results in equal 
bronchoconstriction. Similarly, treadmill running and cycle ergometry, 
produced comparable levels of airway obstruction when performed in the 
47 13 22 
same environment . It is also theorized ’ that the inability of 
swimming to trigger EIA, is yet another manifestation of inspired air 
conditions and its effect on airway cooling. Although vigorous swimming 
generates larger minute ventilations, since the (usually) warm air 
directly above the pool is highly saturated with water vapor, its 
inspiration requires little respiratory conditioning, and therefore, 
minimal heat exchange. 
With the initiating stimulus of EIA thus defined, i.e. heat flux 
with subsequent airway cooling, the logical next question to which this 
present study is addressed, is how does the airway cooling produce 
bronchoconstriction? 
3. Events Following the Initiating Stimulus Responsible for EIA 
Four separate theories have been proposed in an attempt to explain how 
respiratory cooling translates itself into bronchoconstriction. 
a. Direct thermal effect on smooth muscle 
48 Souhrade et al. , investigated the effect of temperature on the 
electrophysiologic and contractile properties of airway smooth muscle. 
After incubating guinea pig and bovine bronchial smooth muscle at various 
temperatures (40°, 37°, 29° and 21°C), for 60 minutes, they found 
significant progressive decreases in resting membrane potentials as the 
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temperature was lowered. They also noted a marked and progressive 
increase in sensitivity to histamine induced contraction as the temperature 
42 
was decreased. They theorized, (based on Deal's " demonstration of reduced 
intrathoracic temperatures using esophageal temperature probes) that 
exercise and hyperventilation, by cooling the bronchial muscle, could 
lower their membrane potentials and lead to depolarization, contraction 
48 
and bronchial obstruction. Thus, they postulated that EIA was caused by 
cold induced smooth contraction alone. 
Though elegant in its simplicity, Souhrada's theory cannot explain 
the time course of EIA. After exercise ceases, the intrathoracic airways 
42 
reattain their resting temperature within 5 minutes . Yet, bronchocon- 
striction progressively worsens several minutes postexercise, and lasts a 
total of 30 to 60 minutes"^. This indicates, that even if in vivo 
temperatures were to reach low enough levels to cause spontaneous de¬ 
polarization of the smooth muscle cells, other mechanims must be operating 
to sustain the contraction. 
b. Adrenergic Receptor Imbalance 
49 50 Drawing upon the conclusions of Jones , Patel et al. theorized 
that EIA was a consequence of altered alpha and beta adrenergic receptor 
ratios in the asthmatic's airway. They postulated that catecholamines 
released during strenuous physical exertion acted on the predominant 
(perhaps thermally regulated^) alpha receptor causing bronchoconstriction. 
They supported this theory by demonstrating the prophylactic efficacy 
of thymoxamine (an alpha blocker) pretreatment in EIA. These results 
corroborated those of Bianco et al. , who prevented postexercise 
obstruction using the alpha blocker indoramin. More recently, however. 
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52 Barnes et al , pointed to the multiple pharmacologic actions of both 
thymoxamine and indoramin in addition to their alpha antagonism as 
52 probably confounding earlier findings. They then demonstrated 
significantly reduced postexercise obstruction, by administering 
aerosolized prazosin, a specific alpha blocker. However, prazosin's 
failure to prevent histamine induced bronchoconstriction led them to 
theorize that its action resulted from blockade of mast cell alpha 
receptors, inhibiting mediator release, and thus preventing EIA, and not, 
as a consequence of correcting an adrenergic receptor imbalance in airway 
49-51 
smooth muscle as previously proposed . The most potent evidence 
militating against the role of adrenergic imbalance in the pathogenesis 
53 
of EIA is derived from another study by Barnes et al. , who demonstrated 
the failure of circulating catecholamines to rise altogether in hyper- 
53 
ventilation induced asthma. They , also pointed out, that since intra- 
pulmonary sympathetic innervation had yet to be demonstrated in man, 
prophylasix of EIA by alpha blockers could not possibly be attributed to 
direct inhibition of alpha mediated bronchoconstriction and, therefore, 
proposed that mast cell degranulation was the operative mechanism instead. 
' 
15 
. C. Role of Reflex Vagal Bronchoconstriction 
The notion of a thermal stimulus activating irritant receptors in 
the airways, resulting in reflex bronchoconstriction, is consistent 
with studies^5 demonstrating that chemical or mechanical stimulation of 
these afferent nerves in the pharynx, trachea, and bronchi do indeed 
trigger vagal mediated airway narrowing. In fact, ten years prior to 
formulation of the heat flux hopothesis11, Simonsson et al 54 suggested 
reflex mediation of cold induced airway obstruction . In a study 
comparing the prophylactic efficacies of ipatropium bromide (an 
anticholineergic agent) and cromolyn sodium in EIA, Thompson et al 56, 
subdivided his asthmatic subjects into two groups. In those patients in 
wham the main anatanic site of airflow limitation (as determined by 
changes in density dependence of MEF rates) was the lower airways, 
ipatropium bromide failed to prevent postexercise bronchoconstriction. 
However, significant inhibition of the postexercise fall in FEV} was 
demonstrated in those subjects with principally large airway narrowing. 
They concluded therefore, that upper airway-exereise induced 
constriction was mediated by vagal reflexes. 
These findings were partially corrobroated byMenally et al.57, 
who attempted to abolish afferent impulses originating in the irritant 
receptors by using oropharyngeal anesthesia during exercise. Since 
administration of 296 lidocaine did in fact prevent EIA in several of 
the subjects studied (though not all), they concluded that reflex 
bronchoconstriction was involved in the pathogenesis of EIA. However, 
in a similar study by Enright et al 58, jt was noted that those 
individuals in whom upper airway anesthesia successfully prevented EIA 
had generated far smaller minute ventilations than subjects who 
. 
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subsequently developed bronchospasm. Enright’s conclusion that upper 
16 
airway anesthesia abolished EIA was soon criticized , since he had 
merely effectively redemonstrated the critical stimulus of 
hyperventilation with subsequent airway cooling as the trigger of EIA. 
Additional doubts as to the role played by reflex 
bronchoconstriction in EIA were raised by Breslin et al59. Although 
confirming the findings of Thompson et al56, by demonstrating 
atropine's ability to prevent flow obstruction in the upper airways, 
they attributed this effect however, not to a cholinergic blockade, but 
rather to the drugs capacity to acutely transfer the site of 
obstruction to the lower airways, by interfering with the heat transfer 
of the upper bronchi. Similarly, despite using large doses of 
atropine, Deal et al^1 were unable to demonstrate any inhibitive effect 
on cold air potentiatin of EIA. Thus, although there is controversial 
evidence implicating some role for vagal mediated reflex 
bronchoconstriction in EIA, it is doubtful that this will be proven to 
be more than a limited one, necessitating finding other operating 
pathogenic mechanisms. 
D. Role of the Mast Cell and Its Mediators In EIA 
The central role of mast cell derived chemical mediators in the 
Type I immediate hypersensitivity reaction in man has been well 
documented^. The pathophysiologic events leading to 
bronchoconstriction in allergen induced asthma has similarly been 
determined to be dependent upon the immunologically mediated release of 
these mast cell substances^. Although it is not suggested that an IgE 
dependent mast cell degranulation occurs in EIA, many have focused on t 
he possibility of a non immunogenic release of these mediators and their 
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subsequent effects on the airway in their search for the ultimate mechanism 
of postexercise bronchoconstriction^, 12,13,22# 
1) Background - The Mast Cell and its Mediators 
(i.e. histamine, SRS-A, PCS) 
Mast cells are present in the human lung, in the bronchial lumen and 
mucosa in concentrations averaging l-7x 10^ cells/gram of pulmonary 
tissue^O. Each cell possesses hundreds of metachromatically staining 
granules containing an array of proteins, peptides, amines and complex 
polysaccharides, with chemotactic, vasoactive and bronchospastic 
properties^l. Once activated, the mast cell releases these performed 
granules elements (i.e. histamine, eosinophil chemotactic factor of 
anaphylaxis, neutrophil chemotactic factor) and subsequently generates and 
then secretes an array of newly formed mediators of inflammation (i.e. 
prostalgglandins and leukotrienes62. The surface of the mast cell is 
studded with 50-300,000 receptors for the Fc portion of IgE, as well as 
other receptors for: acetylcholine, prostaglandins, alpha and beta 
adrenergic compounds and histamine itself3>63* 
The classic inmunologically dependent degranulation of mast cells 
occurs when pairs of adjacent cell bound pairs of IgE are bridged by 
divalent antigen. This induces a sequence of poorly defined membrane events 
which trigger the activation of adenyl cyclase and the subsequent formation 
of CAVIP. This in turn leads to a series of intracellular protein 
phosphorylations eventuating in an energy dependent calcium ion influx into 
the cell culminating in exocytosis^9>63. 
Of specific import to the role of mediators in EIA, it has been 
determined that mast cells may also be non immunogenically activated by 
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such stimuli as enzymes, inophores, polycationic amines, proteins, 
radiocontrast media and most notably cold^S,64# 
The activation of the mast cell, however, is more complex than has been 
intimated above. Modifying the effects of various degranulatory stimuli, is 
an elegant intracellular regulatory mechanism. This regulation is 
predicated upon the existence of two funcitionally different classes of cell 
surface receptors (mentioned previously). One group of receptors, specific 
for PGE, histamine (H2) and beta adrenergic compounds, when occupied, 
activates membrane adenyl cyclase, forming CAMP. The second class, 
consisting of cholinergic and alpha adrenergic receptors, mediate the 
activation of membrane guanvl cyclase and formation of CGVpl3,63. jn ^he 
preactivated (or resting) mast cell, elevations of intracellular CAMP 
inhibits subsequent excitation and degranulation of the cell with release of 
its mediators. Alternatively, reduction of CAMP by the enzyme 
phosphodiesterase, as well as elevation of intracellular OCMP levels, 
potentiates activating stimuli and degranulation^, 63. Knowledge of these 
regulatory phenomena have allowed for a greater understanding of the 
antiallergic and antiasthmatic therapeutic efficacy of the adrenergic and 
methylxanthine compounds. 
The two classes of mast cell deriverd mediators believed to play a 
central and direct role in the pathogenesis of asthma are: the products of 
arachidonic acid metabolism, and the biogenic amine, histamine. 
2) The Role of Arachidonic Acid Metabolites in Asthma 
Inman, arachidonic acid (5,8,11,14-eicosatetraenoic acid) is the most 
abundant precursor from which the prostaglandins, thromboxanes and 
leukotrienes are derived^. After its mobilization from cellular 
phospholipid stores by the enzyme phospholipase A2, arachidonic acid can be 
• 
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converted either to the prostaglandins and thromboxanes via action of the 
enzyme cyclooxygenase, or alternatively, it can be metabolized by the 
lipoxygenases to the hydroxy acids (i.e. HETE) and the leukotrienes(formerly 
known as SRS-A) 
In terms of the effects of the prostaglandins on airway smooth muscle, 
those of the F series as well as the thrombaxanes are (in general) extremely 
potent bronchoconstrictors, whereas those of the E group (and possibly 
prostacyclin) are bronchodi lators66. Thus, as might be expected, following 
IgE dependent activation of human lung tissue in vitro, a predominance of 
the bronchoconstricting PGFo is recovered, along with smaller quantities of 
the bronchodilatory PGE266. Similarly, when challenged, asthmatic patients 
demonstrate a particular sensitivity to PGF2 and undergo severe 
bronchospasm, whereas aerosolized PGE^, administered to the same subjects, 
has a bronchodi1atory capacity exceeding that of isoproterenol66. 
Furthermore, the above actions of the prostaglandins are those independent 
of their capability to interact with mast cell receptors (i.e. PGE) in a 
modulatory capacity by affecting formation of intracellular cyclic 
nucleotides^6’66. 
Although the prostaglandins are of obvious significance in the 
asthmatic diathesis, an even greater import has been ascribed to SRS-A (slow 
reacting substance of anaphylaxis), an acid, hydrophilic, sulfur containing 
lipid of m.w. 400, derived from arachidonic acid via the lipoxygenase 
pathway6^. Unlike histamine which is stored in the metachromatic granules 
and released by exoeytosis, SRS-A is a short lived newdy generated chemical m 
ediators secreted by mast cells as well as other leukocytes (i.e. 
neutrophi1)»6?. In addition to its (in vitro) demonstrated capacity 
to independently cause a slow sustained contraction of smooth muscle as 
. 
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well as an increase in vascular permeability, SRS-A is also known to 
synergistically enhance the spasmogenic and vasodilatory capacity of 
histamine62,69. Other studies have demonstrated SRS-A's predilection 
for lower peripheral airway constriction with less effect on the 
central and larger airways67. 
Implicating SRS-A in the pathogenesis of asthma are the published 
effects of two drugs. Ketotifen, a newly developed 
antiallergic/antiasthmatic preparation with demonstrated therapeutic 
efficacy, has been shown to inhibit the release as well as the 
spasmogenic effects of SRS-A in asthmatic patients116. The other, 
diethylcarbamazine pamoate, a semispecific SRS-A antagonist, has been 
shown by Sly et al.71 to inhibit E1A in fifteen children tested. 
Evidence for prostaglandin participation in EIA is currently lacking, 
as Anderson et al 72 as well as Field et al72 failed to demonstrate 
significantly increased serum levels of either PGF2 or PGE> in 
patients experiencing postexercise bronchoconstriction. 
The importance of in vivo assessments such as these for the 
products of arachidonic acid as well as the need to develop specific 
inhibitors and antagonists has recently been emphasized by Goetzl76. 
He cautioned avoidance of early conclusions regarding the roles of 
arachidonic acid metabolites in inflammatory reactions, despite their 
demonstrated contractile and vasoactive properties, until the phenomena 
observed in vitro are confirmed by in vivo studies. 
Thus although a role for the prostaglandins and SRS-A in the 
pathogenesis of asthma is certainly likely, its exact delineat ion must 
await further accumulation and integration of experimental information. 
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3) The Role of Histamine in Asthma 
Histamine, or B-aminoethylimidazole, formed by decarboxylation of 
the amino acid histamine, is the principal biogenic amine stored along with 
a heparin-protein complex in the secretory granules of mast cells and 
basophiIs74>75. Histamine was first isolated by Best, Dale, Dudley, and 
Thorpe from lung and liver extracts, but was soon shown to be present in 
numerous other tissues studied, and thus acquired its name from the Greek 
word for tissue -histos74. 
The very earliest observations regarding the pharmacologic properties 
of this agent, revealed its dual capacity to stimulate smooth muscle 
contraction as well as cause vasodilation74. The potential role of 
histamine as a mediator of inflammation was soon underscored by Lewis when 
he described the now classic "triple response" phenomenon, occurring 
following its intradermal injection, as well as identifying the release of 
this "H-substance" from skin following immunologic and injurious 
reactions74> 7&- 
More recently, Ash and Schild77 in an attempt to organize and 
understand the myriad of actions of this amine, postulated the presence of 
two different histamine receptors - H^ and H2. This, they realized, would 
explain why certain histaminic responses, such as gastric secretion failed 
to be inhibited by the classic (H^) antihistamines (i.e. pyrilamine). Black 
et al.7^ then identified selective H^ and H2 agonists, and of greater 
therapeutic significance demonstrated the effects of the selective H2 
receptor antagonist - burimamide. 
Although many of histamines actions were determined to be mediated by 
either the H^(i.e. smooth muscle contraction) or H2 receptor (i.e. gastric 
secretion), it soon became apparent that a significant number of its effects 
■ 
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(i.e. vasodilation, lowering blood pressure) were consequences of the in¬ 
teraction of histamine with both of its receptor.s78. 
The first observations implicating histamine in the pathogenesis 
of asthma, were those of Weiss et al.8^ who noted that small amounts 
of the amine produced a "definite bronchial constrictor effect in 
patients with bronchial asthma." This was redemonstrated by Curry88, 
who like Weiss8^ found asthmatics to be much more sensitive to the 
bronchospastic effects of histamine than normal subjects. 
The exquisite sensitivity of asthmatics to even small doses of 
histamine78 is in fact so characteristic of the asthmatic diathesis, 
that inhalation challenges using the amine have gained wide acceptance 
as a means of diagnosing it84. 
Not satisfied that histamine's acknowledged ability to constrict 
airway smooth muscle indicated a pathogenetic role for it in asthma, 
Bleecker et al.88 set out to assess whether histamine inhalation induced 
other pulmonary changes found in spontaneous asthma attacks. They found 
that inhalation of the amine did in fact produce marked alterations in lung 
volumes (i.e. increased FRC and TLC, and decreased VC) and pulmonary 
mechanics as well as bronchoconstriction. They further demonstrated88 that 
unlike animal studies in which histamaine induced bronchoconstriction was 
shown to be mediated by vagal reflex pathways, pretreatment with atropine 
failed to alter the asthmatic's responses to histamine, indicating a direct 
smooth muscle effect. They concluded, therefore,83 that spontaneous asthma 
attacks can be accurately reproduced by the direct actions of inhaled 
histamine. However, in a challenge of asthmatics, intravenously infusing 
histamine, Brown et al.84 only found significant bronchospastic effects on 
subjects whose preehallenge pulmonary function was already depressed. 
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similarly, Kaliner et al.85 demonstrated a significant fall in the PEFR in 
only one of six asthmatics undergoing histamine infusion. These 
studies^,84,85 thus imply, that the asthmagenic potential of 
histamine, is to a large degree dependent on the route of its 
administration. Conceivably, local intrapulmonary concentrations of 
histamine sufficient to reproduce asthmatic attacks, can only be achieved by 
inhalation of the amine but not by systemic infusion. This is not to say, 
however, that locally elevated concentrations of histamine cannot also be 
detected systemically, as shown by Barnes et al., who gave further 
credence to histamines putative role in asthma by demonstrating elevated 
plasma levels of the amine during episodes of nocturnal wheezing. 
In attempting to identify the receptor mediating histamine induced 
bronchoconstriction, Casterline et al.8? utilized the specific Hj 
antagonist, diphenhydramine. By administering this drug prior to the 
histamine challenge, they were able to significantly block its 
bronchospastic effects. They concluded, therefore, that receptors in the 
human bronchial mucosa mediate histamine induced asthma. They additionally 
confirmed the findings of Bleecker et al.^3 by demonstrating atropine’s 
inability to inhibit the induced bronchoconstriction as did the histamine 
antagonist. 
Further clarification of the roles of histamine receptors in the human 
lung was provided by Nathan et al.^9. They demonstrated that alternating 
pretreatment with an and then an H2 antagonist yielded opposite effects 
on histamine induced bronchoconstrietion. Specifically, administration of 
chlorpheniramine, a specific antagonist, significantly increased the 
threshold dose of histamine required to produce bronchospasm. Blockage of 
pulmonary H2 receptors with cimetidine, however, significantly decreased the 
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threshold dose of inhaled histamine needed to produce an equivalent 
fall in the FEV^. They concluded, therefore, that receptors in the 
airways of asthmatics mediate histamine induced bronchoconstriction whereas 
H2 receptors when activated by the same amine induce bronchial relaxation. 
Schachter et al.90 corroborated and then extended these findings in a study 
on histamine receptors in normal as well as asthmatic subjects. After 
determination of a threshold C’T") dose of histamine inducing a 20% fall in 
the MEF40%(P), the effects of oral pretreatment with antihistamines were 
studied. As expected, in both asthmatic and healthy subjects, 
chlorpheniramine, significantly reduced the bronchoconstrictive response to 
histamine at the "TM dose. By contrast, however, asthmatics pretreated with 
cimetidine, demonstrated significantly increased bronchoconstriction after 
administration of the "T" dose of histamine, whereas the response of healthy 
subjects to cimitidine was equivalent to changes seen after placebo 
pretreatment. Thus, they^O concluded that although both asthmatic and 
healthy subjects possessed receptors mediating histamine induced 
bronchocostriction, it was only the asthmatics, who additionally 
demonstrated H2 receptor activity mediating bronchodilation. 
The complexity of the roles of histamine receptors in asthma is further 
underscored by the presence of H2 receptors on the mast cells 
themsel ves^, 91 # it is postulated-^, that histamine, once released from mast 
cells (and basophils) can, by virtue of an integrated negative feedback 
control system, bind to the H2 receptors of the mast cell activating adenyl 
cyclase, thereby raising the intracellular level of CAMP and consequently 
inhibiting any further mediator release. Clinically, however, histamine has 
been firmly established as bronchoconstrict i ve and asthmagenic^. Despite 
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these observations, controversy exists regarding histamine’s role (as well a 
s the role of other mast cell mediators)in the pathogenesis of EIA. 
4. Evidence for Role of the Mast Cell and Its Mediators in EIA 
For many years, evidence implicating mast cell degranulation and 
mediator release in the pathogenesis of EIA was derived from two prominent 
features of this phenomenon. One line of evidence concerned the therapeutic 
efficacy of cromolyn sodium in the prevention of EIA (when administered 
prior to exercise), and the other was drawn from observations concerening 
the so called "refractory period"92. 
The notion of a refractory period in EIA (a fixed time interval 
following postexercise obstruction during which exercise induced 
bronchospasm could not be elicited)!^ was originally posited by MeNeil et 
al.93. During exercise trials, they noted the inability of successive 
challenges to elicit comparable airway obstruction. They suggested that 
this inability stemmed from the depletion of mediators or enzyme precursors, 
responsible for EIA. Definitive work on the "refractory period" was 
performed by Ednunds et al.^4, in a study designed to delineate the time 
course of recovery of the ability to bronchoconstrict postexercise in 
addition to defining the relationship between varying workloads in 
successive exercise trials. Each subject performed identical paired 
exercise tasks separated by varying lengths of time from | - 4 hrs. By 
comparing the percent fall in PEFR following each exercise period, they 
noted marked decreases in the bronchospasm produced by the second exercise 
test when it followed the first one by 1 to 2 hours. Full recovery of the 
ability to bronchoconstrict was found only when the interval between the 
first and second trial was 4 hours. In another protocol, again comparing 
the percent drop in PEFR following successive exercise challenges, they 
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varied the workload of the first exercise period, resulting in graded 
bronchoconstriction responses. They then had subjects perform the second 
exercise challenge at fixed workloads. They demonstrated that the 
response to the second fixed exercise trial was inversely porportional 
to the amount of EIA produced by the initial challenge (i.e. the 
greater the EIA in the first trial the less in the second and vice 
aversa). They concluded, therefore, that EIA resulted from mast cell 
derived mediators, depletion of which, following an exercise challenge, 
resulted in a refractoriness to further postexercise 
bronchoconstriction. Additionally, the release of mediators is not an 
all or nothing phenomenon, but rather, it is graded, in response to the 
varying levels of the exerecise stimulus. And finally, they noted that 
full recovery of a postexercise bronchospastic potential was predicted 
on mediator resynthesis and accumulation1^94. 
The second line of evidence implicating mast cell derived 
mediators in EIA is based upon the effects of the drug cromolyn sodium. 
Cromolyn sodium (or disodium cromoglycate) was first introduced into 
clinical practice by Altounyan (1967)95, who demonstrated its effectiveness 
in inhibiting the asthmatic response to inhaled antigen. Because the drug 
failed to prevent the spasmogenic effects of histamine, SRS-A, bradykinin, 
and acetylcholine on guinea pig ileum9^, and furthermore, demonstrated no 
capacity to inhibit either the binding of IgE to peritoneal mast cells or 
interaction between antigen and antibody97j its efficacy in preventing 
allergen induced asthma was attributed to a mast cell stabilizing effect, 
resulting in an inhibition of mediator (i.e. histamine, SRS-A) release96,98, 
Attempts to refine this somewhat vague notion of mast cell 
stabilization has prompted some to theorize that the drug actually acts by 
9 
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blocking calcium channels (and thereby interfering with stimulus secretion 
coupling), while others have tried to identify cromolyn sodium induced 
changes in cyclic nucleotides as well as protein phosphorylation^. 
Whatever its underlying mechanism of action, there is general 
agreement^ that it is the drug’s ability to prevent mast cell mediator 
release that is ultimately responsible for its prophylactic effects in 
asthma. 
Soon after Altounyan’s findings^ concerning cromolyn sodium's 
prophylactic efficacy in antigen induced asthma, Davies10^ demonstrated 
an analogous effect in EIA. Later work^O clearly delimited the drug's 
therapeutic usefulness as a prophylastic agent (i.e. administered 
before exercise) with little or no beneficial effects noted when given 
after the challenge. 
In a recent study, Breslin et al.99 were unable to attribute the 
drug's inhibition of EIA to an alteration of the respiratory heat 
exchange mechanism as they had previously demonstrated with the 
anticholinergic agent atropine^l. Instead, they confirmed that 
cromolyn sodium not only blunted exercise induced bronchoconstriction, 
but additionally inhibited cold potentiation of EIA. Moreover, 
Godfrey^ emphasized that since cromolyn sodium administration does not 
alter baseline lung function (i.e. does not cause resting 
bronchodilation) its inhibition of EIA only when administered prior to 
an exercise challenge verifies its capacity to interfere with the 
stimulus for bronchospasm i.e. mast cell degranulation. He1^ 
additionally corroborated the findings of Breslin et al.99 in 
demonstrating that inhalation of the drug did not subsequently prevent 
the exercise associated esophageal temperature decline, and therefore, 
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was not inhibiting EIA by interfering with the initial trigger of 
postexercise bronehoconstr ict ion. Godfrey^, like others^O* 96,98? 
concluded therefore, that the operating pathogenetic mechanism in EIA 
was essentially the same as that described in allergen induced asthma 
(AIA), if one makes allowances for differences in their respective 
"triggers”. Thus antigen binding to mast cell IgE operating in AIA, 
and respiratory heat exchange leading to airway cooling occurring in 
EIA, both serve to activate the mast cell, resulting in degranulation, 
mediator release and subsequent bronehoconstriction. 
Other, somewhat more recent evidence supporting the role of mast 
cell degranulation and mediator release in the pathogenesis of EIA has 
been derived from a study by Soter et al.^4, 0n cold urticaria. In 
their experiment, they found significantly elevated levels of histamine 
and eosinophil chemotactic factor of anaphylaxis in the arms of 
patients that had been induced to form urticarial lesions by immersion 
in cold water. They concluded, that degranulation of sensitized mast 
cells triggered by a thermal stimulus (cold), was the operative 
mechanism in cold urticaria. Appliction of this information to EIA, 
wherein heat flux and airway cooling has been shown to be the 
initiating stimulus11, strongly implicates subsequent non immunologic 
degranulation of mast cells with release of its asthmagenic mediators 
as the critical pathogenetic event resulting in bronchoconstriction. 
Similarly designed studies attempting to correlate changes in 
systemic (mast cell derived) mediator levels with EIA, have yielded 
mixed results1^,101-iO5. The first report, by Graneurus et al.1^1 
measured urine levels of histamine and its metabolite, l-methyl-4- 
imidazoleacetic acid, three hours before and after an exercise 
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challenge. Their failure to detect significant changes can in 
retrospect be attributed to their reliance upon the insensitive and now 
obsolete techniques of bioassay and chromatography. More recently, 
using the more sensitive radioenzyme assay for histamine, as well as a 
modified Boyden chamber assay for neutrophil chemotactic activity, Deal 
et al.12, compared the changes in mediator levels in arterial blood 
following hyperventilation and antigen induced asthma. Although both 
challenges produced the expected and nearly identical alterations in 
lung function, neither was associated with a kinetic increase in 
systemic histamine levels. Since, however, the antigen, but not the 
hyperventilation induced asthma was accompanied by a sustained release 
of neutrophil chemotactic activity, they concluded that mast cell 
derived mediators were only involved in the pathogenesis of AIA. 
However, their inability to demonstrate elevated systemic histamine 
levels even after an antigen challenge, forced them to alternately 
suggest, that local intrapulmonary concentration may not be adequately 
reflected in the systemic circulation and therefore, mediator 
involvement does not have to be ruled out in EIA. This in fact, is 
somewhat analagous to the (see above) inability to demonstrate 
histamine induced bronchoconstriction by systemic infusion^, but 
rather, only via inhalation^, when high local concentrations of the 
amine are more certainly attained. 
In another study, however, McFadden et al.l02# validated the 
utility of measuring systemic histamine levels. They found, that a 
distinct subgroup of asthmatics whose prechallenge arterial histamine 
levels were high (4 ng/ml as compared with 2 ng/ml), and had 
significantly greater impairment of their baseline lung function, 
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localized predominantly to the small airways, subsequently developed 
more severe EIA. However, since neither subgroup then demonstrated any 
significant exercise induced histamine elevations, McFadden et al.102 
seriously questioned the role of mast cell derived mediators in EIA. 
Hartley et al.103 in a similar study, compared the postexercise 
changes in systemic histamine levels in both normal and asthmatic 
subjects. Although they did find that during exercise, mean arterial 
histamine levels rose 48% in asthmatics and 42% in normals, neither 
rise was of statistical significance. It should be pointed out 
however, that neither Deal et al.12 or McFadden et al.102, were able to 
demonstrate any changes of this magnitude. Because they found 
insignificant mediator elevations for both asthmatics and normal 
subjects, Hartley et al.103 concluded that mast cell derived mediators 
did not seem to play a role in EIA, and furthermore, attributed the 
observed elevations to an exercise induced leukocytosis and basophilia 
with a nonspecific histamine discharge. They103 did caution however, 
that until intrapulmonary measurements could be performed to ensure 
that local concentrations of histamine were not dissimiliar to systemic 
levels, participation of this (and other) mediator(s) in postexercise 
bronchoconstrietion could not definitely be ruled out. 
Utilizing their own newly developed radioenzyme assay with 
purportedly improved sensitivity and precision for the detection of 
histamine, Barnes and Brown104 compared postexercise and 
hyperventilation induced changes in venous plasma histamine levels in 
asthmatic and normal subjects. In contrast to the findings of Deal*2, 
McFadden102 and Hartley103, Barnes and Brown demonstrated a very 
significant postexercise elevation of plasma histamine 
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(from 6.2 nmol/ to 4 nmol/ ). They, therefore, rejected the role 
of an exercise induced leukocytosis and basophilia in the etiology of 
the histamine elevation found uniquely in the asthmatic group, and 
concluded that mast cell discharge was critical in the pathogenesis of 
EIA. In the second part of their protocol however, they found, that 
although hyperventilation resulted in nearly identical decreases in 
PEFR, no concomitant histamine elevations were demonstrated as is in 
EIA. On close examination of their protocol, however, it can be 
ascertained that the maximum interval between exercise and 
hyperventilation challenges was less than 2 hours. Thus, by 
rechallenging their asthmatics when they were conceivably partially 
refractory to further EIA^4, Barnes and Brown^4 may have inadvertently 
elicited a diminished histamine release, allowing for a systemically 
nondetectable local elevation, sufficient to cause bronehoconstriction. 
Alternatively, their demonstration of systemic postexercise histamine 
elevations may in fact be a manifestation of exercise induced 
leukocytosis, detectable only in asthmatics whose higher and hence more 
accurately measurable baselines allow for an ehhanced capability to 
determine concentration changes. 
In a more recent study, Lee et al.4^5> by measuring postexercise 
serum concentrations of neutrophil chemotactic factor (NCF), 
successfully demonstrated systemic elevations of a mast cell derived 
mediator. Serial challenges of atopic asthmatics with both treadmill 
exercise and antigen inhalation, resulted in nearly identical kinetic 
elevations of NCF, coninciding with parallel falls in the PEFR and FEV^ 
expected in EIA and AIA. Furthermore, they found that pretreatment 
with cromolyn sodium prevented the postexercise NCF elevation as well 
_ 
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as bronchoconstriction. Additionally, they challenged three atopic 
(but nonasthmatic) individuals, and four normal subjects, using the 
same exercise protocol, and found no elevations of NCF. They thus 
dismissed as very unlikely the possibility that the observed NCF 
elevations occurring in asthmatics only (and not in other atopic 
individuals) were secondary to an exercise induced leukocytosis and 
basophilia. Based upon these observations (i.e. an exercise induced 
kinetic elevation of NCF mirroring the rise produced by antigen 
inhalation, as well as its inhibition by pretreatment with cromolyn 
sodium), Lee et al.105 concluded that mast cell degranulation and 
mediator release was responsible for the pathogenesis of EIA. 
In surrmary, whereas several studies104’105 focusing on 
postexercise changes in systemic mediator concentrations demonstrate 
that exertion as a stimulus for asthma does indeed result in mast cell 
degranulation and mediator release, strongly implicating it in the 
pathogenesis of EIA, others12’102’ , finding no such relationship, 
using both exercise and hyperventilation challenges, seriously question 
mast cell participation in postexercise asthma. Furthermore, since 
none of the investigators were able to demonstrate mediator release 
with hyperventilation12’104, one is forced to question whether this 
challenge is indeed equivalent to exercise as claimed0>11>12>10, or 
alternatively, whether exercise associated histamine and NCF 
elevations104’105 were merely misleading findings. 
Recently, Stearns et al.106, did indeed demonstrate the non 
identity of hyperventilation and exercise challenges in the production 
of EIA. By re-examining the refractory period, they corroborated the 
findings of others93’94, that repeated exercise challenges separated by 
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short intervals results in progressively decreased postexercise 
bronchoconstrictive responses. However, successive trials of eucapnic 
hyperventilation, produced no refractoriness, and resulted instead in 
continuous, consistent posthyperventilation asthma. Stearns1-06, 
concluded therefore, that mediator depletion was not operative in the 
causation of refractoriness to EIA as had been thought10*13,94, but 
rather secondary sympathoadrenal consequences of repeated exercise 
acted to temporarily prevent recurrent bronchoconstriction. 
Supporting the postulate of Stearns et al.106 is the findings of 
Barnes et al.66, who demonstrated that hyperventilation is not 
associated with the catecholamaine elevations found during vigorous 
physical exertion. Thus it is conceivable that other as yet 
unidentified processes might account for elevations in systemic 
mediator concentrations following exercise but not hyperventilation. 
Alternatively, however, one can similarly reason that hyperventilation 
and exercise induced asthma are not mediated by identical pathophysiolog 
ic mechanisms106, and the inability to identify mast cell derived 
mediator elevations in post hyperventilation asthma, has no bearing on 
the findings unique to EIA. 
Using yet another approach to determine the role of mast cell 
derived mediators in EIA, Weiler-Ravel1 et al.92s compared the asthma 
inducing mechanisms of antigen and exercise challenges. In designing 
their protocol, they reasoned that since antigen induced asthma (AIA) 
was mediated by a Type I immediate hypersensitivity reaction with 
resultant mast cell degranulation, serially exercising asthmatics over 
short intervals, rendering than refractory to further EIA, should by 
virtue of mediator depletion, similarly block AIA if challenged with 
• 
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antigen during this refractory period. Their results demonstrated the 
existence of two subgroups, blocked and nonblocked. In 6 of the 12 
asthmatics studied, refractoriness to EIA resulted in an inability to 
cause subsequent AIA, despite a known susceptabi1ity as demonstrated in 
baseline studies. However, the other half of the group (who 
interestingly manifested lower baseline levels of lung function), did 
indeed respond to antigen challenge with a full blown attack of 
brochoconstriction, despite being rendered refractory to EIA. VVeiler- 
Ravell92 concluded therefore, that mast cell degranulation and mediator 
release operates to cause postexercise bronchospasm in one subgroup of 
asthmatics whereas, other as yet to be defined mechanisms mediate EIA 
in the other asthmatics. 
In testing the therapeutic efficacy of a new class of drugs, the 
calcium channel blockers, many investigators10^-112 have attempted to 
clarify the pathogenetic mechanism mediating EIA. A priori, one would 
indeed expect these agents to interfere with postexercise constriction 
at several loci in the pathophysiologic chain of events, already 
determined be calciim dependent processes. Those best identified 
include: activation of mast cells and liberation of its 
mediators107*109, as well as excitation contraction coupling and 
discharge of propogated action potentials in smooth muscle cells112. 
Although administration of sublingual nifedipine by Cerrina et 
al.110 failed to alter baseline bronchial tone, it did, however, 
prevent the exercise induced decreases in PEFR and \max50% found after 
placebo ingestion. Their conclusion110 that calcium blockers prevent 
EIA was corroborated by Patel10^, who administered aerosolized 
verapamil to compare its prophylactic capacity with that of cromolyn 
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sodium. Patel interpreted verapamil's success in reducing the 
postexercise fall in FEV^ even more than cromolyn sodium, without 
affecting baseline airway functioning, as indicating the drugs ability 
to block calcium dependent mediator release in EIA. 
In a complex study designed to answer several questions, Barnes et 
al.111, found that sublingual nifedipine only partially (though 
significantly) inhibited EIA. They also noted however, that a 
significant postexercise rise in venous plasma histamine levels that 
occurred with placebo, was blocked completely by nifedipine. Finally 
they reported that the dose of inhaled histamine required to provoke a 
20% fall in PEFR was nearly doubled when patients were pretreated with 
nifedipine as compared to placebo. They concluded therefore, that although 
the drug seemed to inhibit both mast cell mediator release and bronchial 
smooth muscle contraction, it was not of the therapeutic utility suggested 
by Patell08 and Cerrina111*# Patel1^ then found (as had Barnes et al.111), 
that sublingual nifedipine offered partial but significant protection from 
EIA in nine patients. Additionally, however, he also noted complete 
prevention in four and no protection in two subjects challenged. Despite 
these mixed results, he concluded that calciim ions play a central role in 
EIA, which is inhibited therefore, by nifedipine pretreatment. Finally, in 
an attempt to localize the site of action of the calcium blockers, Patel112 
then examined the effect of verapamil on histamine and methacholine induced 
bronchoconstriction. In contrast to the findings of Barnes et al111, Patel 
discovered that verapamil inhalation failed to alter the provocative 
concentrations of either spasmogen needed to induce a 20% fall in FEV^, and 
its pretreatment thus offered no more protection from this challenge than 
did saline placebo. Combining this data with that determined by him 
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previouslylO^, 109} he concluded that the efficacy of the calcium channel 
blockers in inhibiting EIA, was predicated upon its action on mast cells, 
preventing the release of its mediators. 
In summary then, the mast cell and its mediators have certainly been 
implicated in the pathogenesis of exercise induced asthma, however, further 
work must be done, to clarify the many outstanding controversies and 
inconsistencies in the literature to date. 
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II. Introduction 
The pathophysiologic mechanism(s) mediating the phenomenon of ELA, 
wherein the thermal stimulus of airway cooling brought about by the 
hyperventilation of exercise,11 triggers a bronchospastic attack in 
almost all asthmatic patients cha1lenged,^continues to elude the 
grasp of researchers trying to delineate it. Conflicting and often 
confusing findings concerning the roles of adrenergic receptor imbal¬ 
ance,^ 53 vagax reflexes,^ 5® and temperature dependent smooth muscle 
depolarization^1® in postexercise bronchoconstriction, have led many 
investigators^^1’9^ to implicate the mast cell and its chemical 
mediators in the pathogenesis of this event. However, analysis of the 
accumulated data from the many experimental protocols and designs, 
including the study of: cromolyn sodium9^"1^ postexercise systemic 
mediator concentrations, ^5 ca]_cj_uin antagonists,^® and suc- 
92 
cessive exercise and antigen challenges, does not allow for an unequiv¬ 
ocal conclusion as to the proposed central role of mast cell derived 
mediators in EIA. One such mediator, histamine, has long been known to 
OA 09 
induce bronchoconstriction, and in fact was recently shown to pro¬ 
duce pulmonary changes following its inhalation indistinguishable from 
83 
those occurring in spontaneous asthma. 
Thus, some researchers have begun reassessing the role of anti¬ 
histamines in asthma; in an ironic though obviously refined recapitula- 
£ ^ . £ „ . . 117,118 
txon of the work of Herxheimer. 
It was 35 years ago, soon after he ushered in the modern era in the 
study of EIA,19 that Herxheimer117 compared the therapeutic effects of a 
synthetic catecholamine, aleudrine, with the antihistamine pyranisamine 
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usan 
as 
maleate ( anthisan ), in bronchial asthma. He reported that anth: 
did indeed significantly increase the vital capacity (though not 
much as aleudrine) of asthmatics when administered either orally or by 
inhalation. However, its sedative actions as well as its irritating 
effects when inhaled (1-3 min. coughing and numbness) led him to suggest 
that its use be limited to oral ingestion at bedtime. In a follow up 
study Herxheimer118 delimited the utility of phenergan (a phenothiazine 
with antihistaminic actions) and anthisan specifically for mild to 
moderate asthmatic episodes since he found they were not efficacious in 
severe attacks. Herxheimer's advocacy of including antihistamines in 
the therapeutic regimen for mild asthma fell into disfavor in the 1950's, 
when it had been clearly demonstrated that the antihistamines were them- 
119 
selves bronchospastic agents. This spasmogenic capacity was demonstrat¬ 
ed in man (high oral or 1-3% inhalant concentrations) as well as 
animals. Thus, although most authorities agreed that the antihis¬ 
tamines were of no pharmacologic usefulness in the treatment of asthma, 120 
120 
the controversy quietly smoldered on until the mid 1970's, when Popa, 
in a well controlled study, demonstrated the bronchodilating capacity 
of chlorpheniramine in 10 asthmatic subjects. Popa attributed previous 
negative findings in the literature to poorly designed studies wherein 
the antihistamines were orally administered in insufficient doses. He 
therefore proposed and indeed demonstrated that intravenous administra¬ 
tion of a specific, potent H^ blocker with relatively little sedative 
and anticholinergic effects- chlorpheniramine, at higher than recommended 
doses (10 mg) dilates the bronchi of asthmatic patients. Although of 
sma Her magnitude, he found that 8 mg of orally administered chlorphen' 
120 
iramine was also effective in airway dilatation. He prudently 
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concluded that chlorpheniramine was of definite value in the investiga¬ 
tion of the pathophysiology of asthma, particularly as pertaining to 
the possible role of histamine in the resting tonus of bronchial muscle, 
but not necessarily as a clinically useful therapeutic agent, since 
many subjects experienced drowsiness following its administration. 
19 0 
Although Popa successfully demonstrated the bronchodilatory 
capacity of this alkylamine competitive H-^ receptor antagonist, chlor¬ 
pheniramine, in patients with allergic asthma, the mechanism mediating 
this event remained to be clarified. The "classic" (H-^) antihistamines 
i 
(of which chlorpheniramine is considered among the most potent j not 
only possess the potential to block histamine receptors, but addition¬ 
ally are known to mimic the atropine like drugs in their ability to 
block the muscarinic cholinergic receptors. Thus, one could argue that 
chlorpheniramine induced bronchodilation was mediated by an atropine 
122 like effect were it not for a study by Woenne et al. By alternately 
pretreating asthmatic children with either aerosolized chlorpheniramine 
or ipatropium bromide (an acetylcholine antagonist), and then challeng- 
122 
ing them with histamine or methacholine, they “ determined that chlor¬ 
pheniramine specifically and unequivocably inhibited histamine but not 
methacholine induced bronchoconstriction, thus supporting Popa's 
1 20 
contentions.± 
Despite the proven efficacy of orally or intravenously administered 
120 
chlorpheniramine (8-10 mg) as a bronc'nodilating agent, many research- 
erS116> 123-129 -Lnterested in the effects of antihistamines in asthma 
have turned towards other, less sedating and possibly more potent 
antagonists. One agent, as yet not available in the L.S., clemastine, 
is a member of the benzhydrylether group of antihistamines with purported 
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greater blocking abilities than chlorpheniramine as well as reduced 
CNS depressive actions.123 Theorizing that inhalation of this drug with 
resultant high intrapulmonary concentrations would circumvent the need 
to administer high systemic (i.e. oral or intravenous) and possibly 
sedating doses, Nogrady et al. “ administered aerosolized clemastine 
to 12 asthmatic patients. They found that the mean maximum increases in 
the FEV^ and PEFR (21.17, and 31.27, respectively) were not signif icantly 
different than that produced by administration of salbutamol. They con¬ 
cluded therefore, that inhaled clemastine was an effective broncho- 
dilator. In a follow up study Nogrady et al.,12^ demonstrated the drug's 
specific competitive antagonism to inhaled histamine, without finding 
any protective effect when administered prior to methacholine challenges, 
thus identifying its antihistamic character as that responsible for its 
-jo/ 
bronchodilating effects. They further postulated, concurring with 
Popa,12*3 that low grade mast cell derived histamine release not detect¬ 
able in systemic measurements, caused a mild baseline bronchoconstric- 
tion, which when prevented by administration of an H-^ antagonist resulted 
in the demonstrated bronchodilation. Additionally, they proposed utili¬ 
zation of the antihistamine as a therapeutic agent in the management of 
asthma, since its inhalation was not accompanied by any irritation or 
sedation .123,124 
Their conclusions were strongly contested, however, by Partridge 
et al.,12^ who administered equal and even double doses (as compared to 
Nogrady et al.122,12^) of aerosolized clemastine yet failed to show 
similar consistent and significant bronchodilation, raising serious ques¬ 
tions as to the pathogenic role of histamine as well as the antago¬ 
nist's utility in asthma. 
■ 
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Other researchers^”’ have focused their attention on a new 
tricyclic benzocycloheptathiophene derivative--ketotifen, another drug 
not yet available in the U.S. with purported antihistaminic and anti- 
anaphylactic properties, to determine its potential pharmacologic util¬ 
ity in asthma. 
126 
In a multifaceted trial, Craps et al., demonstrated ketotifen's 
protective efficacy against bronchospasm induced by allergans, hista¬ 
mine and even exercise as well as illustrating its superior long term 
antiasthmatic potential as compared with clemastine and cromolyn sodium. 
Similarly, Beumer^-" found ketotifen to be an effective long term pro¬ 
phylactic agent in the treatment of asthma, while corroborating its 
inhibitory capacity on histamine induced bronchospasm. 
Enthusiasm concerning the addition of ketotifen to the anti¬ 
asthmatic therapeutic arsenal has been recently tempered, however, by 
Groggins et al.1^ who failed to demonstrate its prophylactic superior¬ 
ity to placebo administration in 23 asthmatic children. Additionally, 
Sarsf ield, 1-28 in a recent review, cautioned against premature acceptance 
of ketotifen, while conflicting evidence derived from several thera¬ 
peutic trials remain unresolved. 
Superseding the present controversy regarding the use of ketotifen, 
however, are the fairly well documented pharmacologic characteristics of 
this drug, i.e. a mast cell stabilizer, SRS-A antagonist and a calcium 
channel blocker as well as an antihistamine. Thus, even if future 
studies do indeed find this antiasthmatic compound therapeutically bene¬ 
ficial, its multiplicity of actions precludes advancement and refinement 
of our understanding of the specific pathophysiologic events, particu¬ 
larly mast cell derived histamine release in the pathogenesis of asthma. 
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In summary then, many authorities117,118,120’123’126’127 have gar¬ 
nered evidence supporting the pathogenetic role of mast cell derived 
histamine in asthma by demonstrating the therapeutic efficacy of 
various compounds with antihistaminic activity. However, conflicting 
and contradictory findings of other researchers12^’128,129 using similar 
protocols prohibit conclusive and unequivocable ascription of a major 
pathophysiologic function for histamine in this disease. 
Few studies130’131 have addressed themselves, however, to the 
efficacy of (H^) antihistamine administration in the prevention of exer- 
cise induced asthma. Although Zielinski et al., found that 50 mg of 
thiazinamium given intramuscularly prior to exercise did indeed signifi¬ 
cantly reduce EIA, it remained unclear whether the drug's apparent suc¬ 
cess was attributable to prevention of post exercise histamine induced 
bronchoconstriction, or alternatively a pre exercise inhibition of base¬ 
line histamine bronchial muscle tonus with resultant prechallenge broncho- 
131 dilation. In a more carefully designed protocol, Hartley and Nogrady, 
studied the effects of inhaled clemastine prior to and post exercise in 
10 adult asthmatics. Based upon their finding significantly diminished 
post exertional decreases in the FEV^ and PEFR as compared to placebo 
(12.27c and 12.67c vs. 22.07c and 25.47c, respectively) without noting pre¬ 
challenge bronchodilation, they concluded that histamine was necessarily 
involved in the pathogenesis of EIA. 
The present study was undertaken in an effort to define the role 
(if any) of low grade mast cell degranulation and histamine release main¬ 
taining increased resting bronchomotor tone in asthmatic subjects, as 
well as to determine whether, in fact, airway cooling triggers a large 
scale mast cell mediator release (specifically histamine) which is then 
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responsible for the pathophysiologic manifestations and consequences of 
exercise induced asthma. Additionally, it is hoped that a conclusive 
determination be achieved as to the purported therapeutic utility of the 
"classic" antihistamines in bronchial asthma. 
The antagonist, chlorpheniramine maleate, was chosen for this 
1? 0 
study since it has been unquestionably shown to elicit bronchodila- 
tion in asthmatic subjects, by specifically and unequivocably inhibiting 
1 ?2 histamine induced bronchoconstriction. 
Furthermore, by offering the drug as an inhalant in aerosolized 
ion 
form, it is hoped that the required high intrapulmonary concentrations 
will be achieved while concurrently avoiding the sedating sequelae of 
systemic administration. 
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III. Methods 
A. Sub jects 
Twelve mild asthmatic subjects (9 female, 3 male) were recruited as 
paid volunteers. Criteria for inclusion in the study included a history 
of asthma as defined by the American Thoracic Society,'*' as well as dem¬ 
onstrated EIA during the screening procedure (see below). All subjects 
gave informed consent as approved by the Yale University Human Investi¬ 
gations Committee. Additionally each subject completed a detailed ques¬ 
tionnaire concerning the presence of allergies, chronic bronchitis, EIA 
and use of medications. The collected anthropometric data appears in 
Table 1. Although one of the 12 subjects claimed not to suffer from 
ELA, pulmonary function tests performed five minutes post exercise on 
the screening day (see Table 5) revealed the presence of exercise induced 
asthma in all the subjects (i.e. a minimum of 157= decline in the 
-1 o / 
MEF,407o(P)) • Similarly, baseline pulmonary function parameters revealed 
moderate obstruction commensurate with mild asthma (Table 2). 
B. Pulmonary Function Testing 
Subjects performed forced vital capacity maneuvers using a pneumo- 
1 *3 O 
tachograph-integrator system;1 they inhaled to approximately 50-70 
percent of their vital capacity, and then exhaled as fast as possible to 
residual volume, thereby generating a partial expiratory flow-volume 
(PEFV) curve.^2 The subjects then immediately inhaled to total lung 
capacity and subsequently exhaled as fast as possible to residual volume 
thus generating the maximal expiratory flow-volume (MEFV) curve. All 
generated curves were recorded on a Brush 500 X-Y recorder (Gould, 3054, 
Cleveland Ohio). A programmable marker, set to trigger at one second 
> 
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permitted identification of the forced expiratory volume at one second 
(FEV^) . Analysis of the resultant curves enabled measurement of the 
forced vital capacity (FVC), peak expiratory flow rate (PEFR), and maxi¬ 
mum expiratory flow rates at 60 percent of the vital capacity, below 
total lung capacity on the MEFV curve (MEF^Qy) and PEFV curve 
n O A 
(MEF^oyc(P)) . 14 To facilitate comparisons of the subjects' baseline to 
expected normal values (see Table 2), the maximum expiratory flow rate 
at 507, of the vital capacity on the MEFV curve (Vmax507, or MEF^Qy) was 
determined for the Screening Day only. In order to minimize instantan¬ 
eous variability, all pulmonary function tests were performed in tripli¬ 
cate over three minutes, the results of which were subsequently averaged. 
C. Exercise Challenge 
Exercise studies were performed only if the subject refrained from 
taking his/her usual asthmatic medications (see Table 1) for at least 
12 hours prior to the study. All subjects performed identical exercise 
challenges on a cycloergometer (Monark). 
The subjects were instructed to pedal at a constant speed (20 kilo¬ 
meters per hour) throughout the challenge, while exclusively inspiring 
(through a mouthpiece) air dried by having passed through a column of 
calcium sulfate (Drierite, W.A. Hammond Drierite Co., Xenia, Ohio). 
Random measurements of this column of air revealed an average humid¬ 
ity (+S.D.) of 3.20+0.69, 3.10+0.19, and 3.24+0.49 mmHg on the Screening, 
Antihistamine and Placebo days, respectively (none of the differences 
statistically significant as measured by student's t-test) . Additionally, 
the temperature of the lab itself was controlled resulting in average 
temperatures (+S.D.) of 74.75+4.92, 74.35±3.30, and 75.50+3.51 degrees 
. 
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Farenheit, with no significant differences detected between the three 
study days. At the outset of each challenge, the workload against which 
the subjects pedaled was set at 0.0 kiloponds. After completion of each 
minute of exercise, the subjects' heart rate and minute ventilation were 
recorded (using an electrocardiograph (Hewlett-Packard) and a volume 
meter (American Meter Co., Boston, Ma .) , respectively) and the workload 
subsequently increased by 1/2 kilopond for the following minute. This 
procedure was continued until the subjects fatigued, or their heart rate 
exceeded 150 beats/min. (average of 5-7 minutes of exercise). The 
amount of exercise performed by each subject on the screening day was 
matched on the subsequent protocol days, thus ensuring identical chal¬ 
lenges throughout the study. 
D. Drug Administration 
Chlorpheniramine maleate (Schering, Kenilworth, N.J.) supplied as 
a clear liquid solution in 1 ml vials at a concentration of 10 mg/ml was 
prepared by dilution with normal saline to a concentration of 1 mg/ml. 
Five milliliters of this solution were then placed into an "Acorn" 
nebulizer chamber (Devilbiss, Jamestown, Calif.) for immediate use or 
stored no more than 24 hours in a sealed flask in a dark refrigerator. 
The antihistamine was administered by having subjects inhale (by tidal 
breathing) through a mouthpiece (while wearing noseclips) for a total 
of 5 minutes. The driving force for aerosolization was provided by 
attachment of the Acorn nebulizer to a tank of compressed air, flowing 
at a fixed pressure of 20 pounds per square inch. 
The placebo preparation consisted of 5 ml of sterile normal saline, 
delivered in identical fashion in a double blind random order. Subjects 
* 
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were informed prior to each inhalation that the inhaled solutions were 
capable of causing throat and airway irritation and were instructed to 
continue the drug inhalation even if coughing ensued. Of note, none 
of the subjects were forced to discontinue the drug inspiration because 
of coughing, irritation or other side effects. A total of 10 subjects 
did experience mild transient throat and airway irritation as well as 
1/2-2 minutes coughing while inhaling the chloropheniramine maleate, 
whereas no similar responses were observed with placebo. 
E. Study Design (Figure 1) 
The study consisted of exercise challenges on three separate days; 
an initial Screening Day, and the subsequent two Protocol Days. 
1. Screening Day (Day 1) 
To determine baseline lung function, each subject underwent pre¬ 
exercise pulmonary function testing in triplicate as described above 
(see Table 2). Following this, the subjects were instructed as to the 
use of the cycloergometer, breating apparatus and electrocardiograph. 
They then performed 5-7 minutes of exercise (as described above), after 
which they quickly underwent another series of 3 pulmonary function 
tests (i.e. Immediate Postexercise or PEO'). After a waiting period of 
5 minutes, pulmonary function testing was repeated (i.e. 5 minutes post¬ 
exercise or PE51). Two metered doses (0.65 mg each) of metaproterenol 
sulfate (Alupent^-) inhaler were then administered, which was followed 
after another 10 minute waiting period, by a final set of pulmonary func¬ 
tion tests ((Post Bronchodilator or PBd), Tables 3-5). 
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2. Protocol Days (Day 2 and 3) 
After performance of an initial set of prechallenge baseline pul¬ 
monary function tests, the subjects were administered, on alternate ran¬ 
domly assigned days (in a double blind fashion) the aerosolized solution 
consisting of either normal saline or chlorpheniramine maleate for 5 min¬ 
utes as described. Over the ensuing 30 minutes following the drug 
inhalation, each subject performed 3 sets of pulmonary function tests 
(see Figure 1); the first, immediately postinhalation (PAHO'), the sec¬ 
ond, 10 minutes postinhalation (PAH10') and the third at 30 minutes 
postinhalation (PAH30'). 
After completion of the postinha lational testing, the subjects were 
challenged with the identical exercise task performed on the Screening 
Day. Pulmonary Function testing as well as bronchodila tor administra¬ 
tion were similarly carried out as in the Screening Day (Tables 6-15). 
F. Analysis of Results 
For each of the 12 subjects, the mean values derived from every 
triple set of pulmonary function tests were tabulated into columns 
according to the time locus within the study at which they were per¬ 
formed (i.e. Baseline, PAHO', PAH10', etc.). In addition to calculating 
the mean and standard deviation for each column, comparisons were per¬ 
formed between each time locus and the baseline of that day (% Baseline). 
To assess statistical significance, each time locus for a particular 
day was compared to Baseline using a two tailed paired student's t-test. 
Additional t-tests were performed comparing equivalent loci on the Anti¬ 
histamine and Placebo Days, Antihistamine and Screening days as well as 
Screening and Placebo Days. 
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IV. Results 
A. Screening Dav 
1. Baseline and Post Exercise Pulmonary Function Tests 
Observations recorded in Table 2, reveal moderate (though insignifi¬ 
cant) reductions in the FEV^ and PEFR, as well as a large decrease in 
the Vmax507c (P < 0.001) in preexercise pulmonary function tests as com¬ 
pared to expected normal values, which are commensurate with mild 
as thma. 
As evident in Tables 3-5, comparisons of all pulmonary function 
parameters to their respective baseline values (Z Baseline) demonstrated 
a slight trend towards immediate post exercise bronchod ilation, whereas 
5 minutes post exercise reductions in: The FVC from 4.14 to 3.98 (L) 
(P < 0.05), the FEVl from 3.00 to 2.77 (L) (P < 0.001), the PEFR from 
5.78 to 5.20 (L/S) (P < 0.01) and finally the MEF40%(P) from 2.11 to 
1.51 (L/S) (P < 0.001) all demonstrate the presence of EIA in this group 
of subjects. Additionally, after administration of the bronchodilator, 
all pulmonary function measures either returned to baseline (FVC) or 
significantly surpassed it (i.e. FEV]_, PEFR and MEF^q^P)). Figure 2 
displays the entire sequence of the above pulmonary function changes (as 
measured by the FEV-^ and MEF^q^(P)) for all subjects on the screening 
day. 
B. Protocol Days 
1. Antihistamine Day 
Significant reductions in all pulmonary function tests occurred 
immediately following inhalation of the chlorpheniramine maleate (Tables 
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6, 8, 10, 14), demonstrating drug induced bronchoconstriction. By 10 
minutes postinhalation, however, all parameters returned towards baseline. 
Measurements of pulmonary function 30 minutes after inhalation demonstra¬ 
ted moderate though insignificant increases in the FEV-^ and PEFR (Tables 
8 and 10) as well as a significant increase in the sensitive MEF^^(P) 
(P < 0.05) as compared to baseline (Table 14). Immediately after exer¬ 
cise, although the FVC remained unchanged (Table 6), the FEV^ rose 
(insignificantly) from 2.85 to 3.01 (L) (Table 8), and the PEFR and 
MEF407o(P) both increased significantly from 5.42 to 5.91 (L S) and 1.88 
to 2.37 (L/S) respectively (Tables 10 and 14). Five minutes after the 
exercise challenge, all parameters demonstrated slight and insignificant 
decreases as compared to baseline except for the FVC which dropped by 
0.14 (L) (P < 0.05). Finally, postbronchodilation, all measures of lung 
function significantly increased again except for the FVC which remained 
unchanged. 
2. Placebo Day 
Immediately following inhalation of saline, all pulmonary function 
parameters (Tables 7, 9, 11 and 15) were significantly decreased as com¬ 
pared to the baseline of that day (P < 0.05). Ten minutes later, how¬ 
ever, all measures returned towards the prechallenge values and remained 
at those levels at 30 minutes postinhalation as well. Although all the 
determinants of lung function increased slightly immediately after exer¬ 
cise, no value reached statistical significance. Measurements five 
minutes post exercise revealed a strong, though again insignificant 
trend towards reduced lung function with MEF^q^(P) falling over 16% from 
1.67 to 1.34 (L/S) (Table 14). Finally, all parameters showed marked 
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increases after administration of the bronchodilator (P < 0.01) except 
for the elevation in the FVC which did not reach statistical significance. 
C. Comparison of Antihistamine, Placebo and Screening Davs 
1. Antihistamine and Placebo Days 
Results of the t-tests comparing the FVC, FEV^, PEFR and MEF^q^(P) 
of equivalent time loci on the two protocol days, appear under their 
respective columns in Tables 6, 8, 10 and 14 (i.e. AH ■* PI t-test) . 
Additionally, Figures 5-10 illustrate comparisons of the changes in pul¬ 
monary function for each time locus (as measured by the FEV^ and MEF^q-^P)) 
on the Antihistamine and Placebo days. Finally, composite illustrations, 
demonstrating the entire sequence of changes in, as well as the differ¬ 
ences between, the FEV-^ and MEF^^(P) during each of the protocol days 
appears in Figures 3 and 4. 
Except for the FVC, no significant differences were noted between 
the baseline pulmonary function tests. Although slightly (but not sig¬ 
nificantly) more pronounced on the Antihistamine day, all parameters 
showed similar declines immediately post inhalation on both days (Figure 
5). Figures 3, 4 and 6 demonstrate the parallel return of pulmonary 
function toward baseline which occurred 10 minutes postinhalation of 
both chlorpheniramine and saline, with no significant differences detec¬ 
ted in the other parameters as well (Tables 6 and 10). These parallel 
trends cease, however, by 30 minutes postinhalation, as the FEVj (Fig¬ 
ures 3 and 7) and MEF^0y(P) (Figures 4 and 7) both rise exclusively on 
the Antihistamine day (P < 0.05), demonstrating chlorpheniramine (but 
not saline) induced bronchodilation. Similarly, statistically signifi¬ 
cant differences between the FEV-j^ and MEF^q^(P) observed on the two 
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protocol days were detected immediately post exercise, once again illus¬ 
trating the greater bronchodilation which occurred on the antihistamine 
day (see Figures 3, 4 and 8, and Tables 8 and 14). Although the pulmo¬ 
nary function parameters, FVC and PEFR show similar, parallel discrepan¬ 
cies between the protocol days (i.e. greater bronchodilation occurring 
with the antihistamine 30 minutes post inhalation as well as immediately 
post exercise) these did not reach statistical significance (see Tables 
6 and 10, 7 and 11). 
Of particular note, are the incongruities between the decline in 
the FEV-^ and MEF^q^(P) 5 minutes post exercise on the two days. Whereas 
the FEV^ fell less than 17, and MEF^q^(P) less than 77. relative to base¬ 
line on the antihistamine day, greater declines of 5.257, and 167. in the 
FEV^ and MEF^q^(P) were noted on the Placebo day. Comparisons of the 
absolute values of these pulmonary function tests on the two days clearly 
demonstrated statistical significance (P < 0.01) (see Figure 9). 
Similarly, significant differences between the FVC and PEFR (P < 0.05) 
on the two protocol days measured five minutes after exercise were 
detected as well (Tables 6 and 10). 
In an effort to distinguish between the occurrence of preexercise 
bronchodilation with subsequent bronchoconstriction back to baseline, 
and the actual prevention of postexercise bronchoconstriction (i.e. ELA) 
a separate "delta" calculation was performed. The AFEV^ and aMEF^q^(P) 
representing the mean differences between these pulmonary function 
values recorded 30 minutes post inhalation and 5 minutes postexercise 
of each individual day were found to be 0.12 (L) and 0.57 (L/S) respec¬ 
tively on the antihistamine day, and 0.17 (L) and 0.46 (L/S) on the 
placebo day. These values were not significantly different, nor were 
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there any such differences between the two protocol days noted for the 
AFVC and APEFR. Examination of Figures 3 and 4 similarly reveal that 
although the 5 minutes postexercise values of the FEV^ and MEF^q^P) 
merely return to baseline on the Antihistamine day, their drop from 
their PAH30' values were essentially the same as those occurring on 
the Placebo day. 
Finally, pulmonary function tests performed postbronchodilation, 
on the Antihistamine day, revealed significantly greater airflow as 
measured by the FEV]_ (P < 0.01, see Figures 3 and 10) as well as increased 
(but not statistically significant) values for the FVC, PEFR and MEF^qC/(P) 
compared to the Placebo day. A similar "delta" calculation performed by- 
subtracting the pulmonary7 function values obtained 5 minutes postexer¬ 
cise from those obtained postbronchodilation on each separate day again 
failed to reveal a significant difference between the two protocol days. 
2. Antihistamine and Screening Days 
Although the FEV-^ on the Screening day dropped over 8% below base¬ 
line 5 minutes after exercise, whereas a less than 1% fall from baseline 
occurred on the Antihistamine day, comparison of the absolute pulmonary 
function values revealed no significant differences between the two days 
(see Tables 3 and 8). Similarly, the greater percent fall in the 
MEF407o(p) from baseline on the Screening day, 5 minutes postexercise 
(28.527o) as compared to the Antihistamine day (6.23%) did not reach 
statistical significance when the absolute values were compared. 
3. Placebo and Screening Day's 
Although comparison of all baseline pulmonary function values reveals 
significantly greater prechallenge bronchoconstriction on the Placebo day 
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(Tables 7, 9, 11 and 15), examination of the percent falls in the FEV-^ 
and MEF407o(P) on the two days demonstrates the parallel and statistically 
equivalent changes occurring between baseline and 5 minutes postexercise. 
Thus the 8.37% drop, and a similar 5.217. fall in the FEV^ on the Screen¬ 
ing and Placebo days respectively (Tables 3 and 9), as well as a 28.527c 
Screening day decrease and 16.02% Placebo day decline in the MEF4q^(P) 
all serve to demonstrate the slight (but statistically insignificant) 
reduction in EIA on the Placebo day. 
D. Minute Ventilation 
Summation of the total minute ventilation generated by the 12 sub¬ 
jects performing identical exercise tasks on the Screening, Antihista¬ 
mine and Placebo days resulted in mean values of (IS.D.) 158114, 144116 
and 148ll6 (L) respectively. Comparison by way of a two-tailed, paired 
student's t-test revealed no significant differences in ventilation 
between any pair of days during the study. Similarly, no significant 
differences were found when both the baseline and final minute ventila¬ 
tion were compared for the three study days. The mean baseline values 
(Is.D.) were calculated to be: 9.5913.92, 10.50l4.23 and 11.2513.49 
liters, whereas the mean final minute ventilation (IS.D.) were deter¬ 
mined to be: 41.59lll.75, 37.42110.60, and 39.50ll3.72 liters for the 
Screening, Antihistamine and Placebo days, respectively. 
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V. DISCUSSION 
A. The Exercise Challenge 
Results of pulmonary function testing on the screening day (Figure 2) 
serve to redemonstrate the classic and expected sequelae1^>^4 of an 
exercise challenge in asthmatics. Following an initial transient mild 
improvement in airway function all asthmatic subjects responded, 5 minutes 
after exertion, with significant reversible bronchoconstriction. In an 
effort to ensure consistency and reproducibility, each subject identically 
reproduced the exercise challenges on each of the 3 study days. Similarly, 
to guarantee equivalent thermal burdens^’22, laboratory temperature, 
inspired air humidity as well as total ventilation were matched and remained 
statistically constant throughout the study. Finally, subjects were 
requested to undergo the 3 exercise challenges at approximately the same 
time each day to avoid potential diurnal variation. 
B. Effect of Inhaled Chlorpheniramine 
1. Initial Bronchoconstriction 
Inhalation of chlorpheniramine maleate clearly caused mild, transient 
bronchoconstriction (Figures 3-5), an effect not unexpected in view of 
similar findings with other antihistamines by Herxheimer^ ‘ * an(j 
Hawkins11^, a parallel, significant, immediate post saline-placebo 
inhalation bronchospasm also occurred. (Figures 3-5). Whether psychogenic 
or physiologic in origin (i.e. loosening of viscous secretions or 
stimulation of irritant receptors), the mechanism of this 
bronchoconstriction may similarly underlie, to an indeterminate extent, the 
post antihistamine airway narrowing as well. Nevertheless, the exclusive 
occurrence of coughing and airway irritation as well as the development of 
greater (though not significantly) airway obstruction after chlorpheniramine 
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inhalation, necessitates at least partial attribution of the cause of post 
inhalation bronchoconstriction to a direct and unique irritant effect of the 
antihistamine itself. 
2. Recovery and Bronchodilation 
Despite the initial reduction of airflow, by 30 minutes post 
inhalation, the effect of chlorpheniramine was clearly and unequivocably 
bronchodilatory in nature (Table 14, Figure 4 and 7), consistent with the 
findings of Popa1^. However, by aerosolizing a solution of the drug, and 
administering it via inhalation, thereby (apparently) achieving sufficiently 
high local intrapulmonary concentrations to effect histamine blockade 
without resorting to the usage of high systemic doses, we circumvented the 
troublesome sedating activity reported by others117 » 113,120 # 
3. The Exercise Challenge 
By recording pulmonary function at various intervals following the 
antihistamine inhalation, prior to the exercise challenge, we have 
demonstrated the blocker’s ability to improve airway function in 
asthmatics, by raising their flow rates to a new higher baseline level. 
This was clearly shown by demonstrating significant differences between the 
PAH 30' pulmonary function tests on the antihistamine and placebo days 
(Figures 3, 4 and 7). However, although comparisons between the absolute 
values of the FEVi (measuring predomonantely large airway function134) and 
the MEF40%(P) (measuring predominately small airway function134) at 5 
minutes after exercise on the protocol days revealed significantly decreased 
lung function on the placebo day (Figures 3, 4 and 9), we are forced to 
conclude that the antihistamine did not prevent or inhibit the development 
of EIA. Analysis of Figures 3 and 4 (particularly Figure 4) reveals a sharp 
decline in lung function between the 30 minutes post antihishistamine 
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inhalation - preexercise challenge and the 5 minutes post exercise recording 
of airway functioning. Similarly, the absolute decline in the MEF40%(P) 
from the PAH30' value to the PE5' value (i.e., the MEF40%(P)) of 0.57 (L/s) 
on the antihistamine day, actually surpassed the MEF40%(P) value on the 
placebo day of 0.46(L/s). Thus, although comparisons of the PE5' to 
baseline pulmonary function values on the antihistamine day reveal no 
significant bronchoconstriction, this merely reflects a prechallenge 
elevation to a new baseline level (i.e. PAH30’) from which a large fall in 
pulmonary function did in fact occur following exercise. 
It should be noted, however, that the fall in the FEV^ from PAH30' to 
PE5 ’ (i.e. FEV]^) on the antihistamine day of 0.12 (L) as compared to a 
0.17(L) decline on the placebo day, did demonstrate an insignificant yet 
observable trend of decreased large airway post exercise bronchoconstriction 
with chlorpheniramine inhalation (see Figure 3). 
4. Use of a Bronchodilator 
Although chlorpheniramine maleate inhalation induced significant 
bronchodi1 at ion (Table 14) not matched by placebo control (Figure 7), this 
effect was quite modest in comparison to the marked improvement in airway 
function following administration of the B agonist, metaproterenol (Figures 
3,4 and 10). This demonstrated delimited efficacy of histamine antagonism 
in asthma (i.e. in reversing histamine induced brochoconstriction), though 
consistent with the findings of Herxheimer117»118 and Nogrady et al.123>124’ 
strongly implicate the action of other non inhibited chemical mediators 
(i.e. SRS-A) as well as perhaps other pathogenic mechanisms in this disease. 
5. Comparison to Other Antihistamines 
Our findings support those of Herxheimer117>118» Nogradv123*124> 
Craps11!)’123 an(j Beumer127’ that antihistamine administration reverses the 
;• 
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bronchoconstriction found in asthmatic patients. However, the failure of 
chlorpheniramine to more than mildly bronchodi1 ate the small airways of the 
subjects tested, forces us to agree with those119>125.129.130 who find this 
class of drugs therapeutically inferior to other agents currently utilized. 
That ketotifen has been demonstrated by some researchers119»126,127 j-,ave 
excellent antiasthmatic activity, may in fact be attributed to its other 
pharmacologic properties (i.e. SRS-A antagonism, mast cell stabilization, 
calcium channel blockade). 
The results of the present study do, however, sharply conflict with 
those of Zielinski, et al.180 who found the antihistamine thiazinamiurn, 
efficacious in the prevention of E1A. However, as pointed out by 
Hartley181’ it remained unclear from the data generated by Zielinski et 
ai.1-30, whether actual inhibition of post exercise bronchoconstr ict ion 
occurred, or alternatively they merely observed the prechallenge 
brochodilatory capacity of the antihistamines as demonstrated in the present 
study. Administering aerosolized clemastine, however, Hartley and 
Nogrady181 reported antihistaminic inhibition of E1A without elevating the 
prechallenge baseline. Thus results of the present study conflict with 
those of Hartley and Nogrady181 on two major points. First, we do in fact 
find that antihistamines (H^) cause mild prechallenge bronchodi1 ation, and 
second they fail to prevent EIA. These differences can be reconciled by 
several lines of reasoning. Nogrady et al.128’12-1 and Hartley et al.181 
claim that clemastine is more potent an H^ antagonist than 
chlorpheniramaine, which if true, reimplicates histamine in the pathogenesis 
of EIA and indicates that our inability to prevent EIA was a consequence of 
insufficient H^ antagonism. This seems very unlikely, since we (as have 
others117’118’120^ demonstrated antihistamine induced bronchodilation 
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elevating baseline lung function, whereas clemastine failed to do so in 
Hartley's studylSl. Thus, it may be possible that clemastine's efficacy in 
inhibiting EIA was secondary to an as yet unknown pharmacologic action of 
this drug. 
C. Resting Bronchomotor Tone 
Based upon the demonstrated significant (though mild) bronchodilation 
occurring 30 minutes after chlorpheniramine inhalation, we conclude (as 
intimated by Popa^^O) that jow gra(je mast cell derived histamine release 
contributes to the increase in resting bronchomotor tone found in 
asthmatics. Because administration of metaproterenol resulted in a far 
greater degree of airway dilitation (Figures 3 and 4), we further propose 
that other mechanisms are at play in maintaining increased airway resistance 
in asthmatic patients. Whether this non histamine induced 
bronchoconstriction is mediated by other mast cell derivatives (i.e. the 
leukotrienes-SRS-A) or other mechanisms entirely (i.e. increased resting 
vagal efferent tone!35) remains to be clarified. 
D. Histamine and EIA 
As a result of the potent H^ antagonist - chlorpheniramine maleate's 
inability to inhibit EIA, despite achieving sufficient local intrapulmonary 
concentrations to cause prechallenge bronchodilation after its inhalation as 
an aerosolized solution, we conclude that mast cell derived histamaine does 
not play a major role in the pathogenesis of postexercise asthma. 
Furthermore, because this mode of delivery of the antihistimine resulted in 
significant prechallenge bronchodilation of the smaller airways (i.e. 
significant increase in the MEF40%(P)134) we cannot attribute its inability 
to prevent EIA to a failure in drug delivery to the more peripheral sections 
of the lung. 
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An unlikely alternate explanation for the full development of EIA, is 
the possibility that the large minute ventilations generated during exercise 
simply washed out the unbound antihistamine solution from the airways 
leading to an overwhelming displacement by histamine, once large scale mast 
cell degranulation occurred. 
E. Mast Cell Perived Mediators in EIA 
In an effort to reconcile the findings of the present study to those 
that have implicated the mast cell and its mediators in the pathogenesis of 
EIA; i.e.: the efficacy of calcium channel blockersl08-112 and cromolyn 
sodiuml3,99,100 jn preventing EIA, the demonstration of cold induced mast 
cell degranulation64) as well as the finding of kinetic elevations in 
postexercise plasma histamine10^ an(j ncf concentrations105 in asthmatics, 
two pathophysiologic scenarios can be proposed. Conceivably, exercise 
induced asthma is in fact the consequence of thermally (cold) induced mast 
cell activation with liberation of its chemical mediators. However, the 
synergistic combination of the leukotrienes (SFtS-A) with histamine°^,69 and 
perhaps certain prostaglandins constitutes a far too powerful 
bronchoconstr i ct i ve and inf larrmatory environment to allow for significant 
inhibition of its sequelae by isolated histamine antagonism. 
Alternatively, it is also possible, that although the mast cell and its 
mediators participate in the pathogenesis of EIA, other as yet to be defined 
mechanisms concurrently operative following respiratory heat exchange and 
airway cooling, contribute to this condition. 
Future studies may do well therefore, to attempt to control and 
eliminate the presumed pertinent mast cell effects, by administering in 
various combinations specific antagonists of SRS-A, prostaglandins as well 
as histamaine, prior to an exercise challenge in order to determine whether 
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EIA is the pathophysiologic consequence of mast cell activation or 
alternatively, whether other processes previously overlooked are responsible 
for postexertional asthma. 
In sunmary, the failure of chlorpheniramine maleate to inhibit the 
development of EIA, eliminates histamine as a independent, central and 
critical mediator of EIA. However, the Hi blocker's capacity to mildly 
bronchodilate asthmatic subjects prior to an exercise challenge suggests 
that low grade mast cell degranulation and histamine release partially 
contributes to the increased resting bronchomotor tone found in asthma. 
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